I initially wrote about the use of GLP-1 analogues in my blog Keeping Your Weight Stable in September 2022. Since then, on an almost daily basis we read about Ozempic (semaglutide), which was licenced for diabetics, then Wegovy (also semaglutide), which was licenced for weight loss, and now Mounjaro (tirzepatide). These drugs cause weight loss by increased insulin levels, appetite suppression, and burning fat. In addition to lifestyle improvements in sleep, diet and exercising, they will play a long-term role in the future of anti-ageing medicine. So what is Semaglutide? It is an analogue of GLP (glucagon like peptide)-1, which …